NovoCure Limited (NVCR) Q3 2026 earnings results
NovoCure Limited (NVCR) reported Q3 2026 results on Oct 29, 2026, 7:00:28 AM ET: GAAP EPS -$0.09 vs. -$0.23 expected (beat by 61.7%); revenue $193.40M vs. $182.23M expected (beat by 6.1%). Outlook: Full-year 2026 net revenue guidance raised to $736 million - $743 million and adjusted EBITDA to $24 million - $34 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.09 | -$0.23 | Beat by 61.7% |
| Revenue | $193.40M | $182.23M | Beat by 6.1% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 7:00:28 AM ET. Nexqual published them 109 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 15.7% from $167.20M; GAAP diluted EPS was -$0.09 vs. -$0.33 (+72.7%).
Stock reaction
The results came out before the market opened. NVCR closed at $13.11 on October 29, 2026, down 7.5% from its $14.17 close on October 28, 2026 before the results.
Questions and answers
Did NovoCure Limited beat earnings expectations?
Yes. NovoCure Limited reported GAAP EPS of -$0.09 against an average analyst estimate of -$0.23 (beat by 61.7%), and revenue of $193.40M against $182.23M expected (beat by 6.1%).
What were NovoCure Limited's Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.09 and revenue of $193.40M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 15.7% from $167.20M; GAAP diluted EPS was -$0.09 vs. -$0.33 (+72.7%).
When did NovoCure Limited report Q3 2026 earnings?
Oct 29, 2026, 7:00:28 AM ET, in an SEC 8-K filing (Item 2.02).
How did NVCR stock react to the earnings?
The results came out before the market opened. NVCR closed at $13.11 on October 29, 2026, down 7.5% from its $14.17 close on October 28, 2026 before the results.
What did NovoCure Limited say about its outlook?
Full-year 2026 net revenue guidance raised to $736 million - $743 million and adjusted EBITDA to $24 million - $34 million.
More on NVCR
NVCR stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:08 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt